On March 5, 2013 MorphoSys published its full year 2012 results and its financial guidance for the current year. For 2013, MorphoSys anticipates total Group revenues between EUR 48 million and EUR 52 million and an EBIT of EUR -18 million to EUR -22 million. This guidance does not include a successful out-licensing of any of the Company's proprietary development programs, which could lead to an out-performance of this guidance. Investment in proprietary product and technology development in 2012 will be approximately EUR 32-37 million.
| in € million | 2013 | 2012 |
| Group Revenues | 48 - 52 | 51.9 |
| Investment in Proprietary R&D | 32 - 37 | 21.7 |
| Group EBIT | -18 to -22 | 2.5 |
